REFERENCES
- Claramunt, R. M., C. López, I. Alkorta, J. Elguero, R. Yang, and S. Schulman. 2004. The tautomerism of Omeprazole in solution: a1H and 13C NMR study. Magnetic Resonance in Chemistry 42(8): 712–14. doi:10.1002/mrc.1409
- DellaGreca, M., M. R. Iesce, L. Previtera, M. Rubino, F. Temussi, and M. Brigante. 2006. Degradation of lansoprazole and omeprazole in the aquatic environment. Chemosphere 63(7): 1087–93. doi:10.1016/j.chemosphere.2005.09.003
- Dev, R. V., G. S. U. Kiran, B. V. Subbaiah, B. S. Babu, J. M. Babu, P. K. Dubey, and K. Vyas. 2009. Identification of degradation products in stressed tablets of Rabeprazole sodium by HPLC-hyphenated techniques. Magnetic Resonance in Chemistry 47(5): 443–48. doi:10.1002/mrc.2404
- Olbe, L., E. Carlsson, and P. Lindberg. 2003. A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole. Nature Reviews Drug Discovery 2(2): 132–39. doi:10.1038/nrd1010
- Reddy, G. M., B. V. Bhaskar, P. P. Reddy, S. Ashok, P. Sudhakar, J. M. Babu, K. Vyas, and K. Mukkanti. 2007. Structural identification and characterization of potential impurities of pantoprazole sodium. Journal of Pharmaceutical and Biomedical Analysis 45(2): 201–10. doi:10.1016/j.jpba.2007.05.032
- Reddy, G. M., B. V. Bhaskar, P. P. Reddy, P. Sudhakar, J. M. Babu, K. Vyas, P. R. Reddy, and K. Mukkanti. 2007. Identification and characterization of potential impurities of rabeprazole sodium. Journal of Pharmaceutical and Biomedical Analysis 43(4): 1262–69. doi:10.1016/j.jpba.2006.10.017
- Sachs, G, J. M. Shin, and C. W. Howden. 2006. Review article: The clinical pharmacology of proton pump inhibitors. Alimentary Pharmacology and Therapeutics 23(s2): 2–8. doi:10.1111/j.1365–2036.2006.02943.x
- Savarino, V., F. D. Mario, and C. Scarpignato. 2009. Proton pump inhibitors in GORD: An overview of their pharmacology, efficacy and safety. Pharmacological Research 59(3): 135–53. doi:10.1016/j.phrs.2008.09.016